From Lab to Life: The Research Behind SAGA's Breakthrough
There's a significant need for improved biomarkers to diagnose cancer, select the best treatment, and monitor patient response. Traditionally, this has involved invasive tissue biopsies. However, Dr. Lao Saal's research group was interested in the potential of liquid biopsies—taking samples from fluids such as blood. Based on their leading research in this field, Dr. Lao Saal and Anthony George founded SAGA Diagnostics in 2016.
SAGA Diagnostics is pioneering ultra-sensitive liquid biopsy tests to detect cancer recurrence early and tailor treatments to individual patients. Their proprietary technology, which analyzes circulating tumor DNA (ctDNA), allows them to create tests that are far more sensitive than other liquid biopsy tests on the market.
Remarkable Results
The results are remarkable. Their test, Pathlight™, has shown 100% accuracy in detecting early breast cancer recurrence, providing a 13.7-month head start to treatment.
Now Launched in the U.S.
SAGA Diagnostics announced the commercial launch of Pathlight™ in the U.S. at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, held from May 30 to June 3.
Pathlight™ has been submitted for U.S. reimbursement via the MolDX Program and is analytically validated across multiple cancer types. The test is already being used successfully in clinical studies by top pharmaceutical companies and at preeminent academic institutions and national cancer centers.
Want to know more? Read the full press release from SAGA: https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/